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Abstract
Background: The diagnosis of hyperglycaemia in sub-Saharan Africa (SSA) is challenging. Blood glucose levels
obtained during oral glucose tolerance test (OGTT) may not reflect home glycaemic profiles. We compare OGTT
results with home glycaemic profiles obtained using the FreeStyle Libre continuous glucose monitoring device
(FSL-CGM).
Methods: Twenty-eight women (20 with gestational diabetes [GDM], 8 controls) were recruited following OGTT
between 24 and 28 weeks of gestation. All women wore the FSL-CGM device for 48–96 h at home in early third
trimester, and recorded a meal diary. OGTT was repeated on the final day of FSL-CGM recording. OGTT results were
compared with ambulatory glycaemic variables, and repeat OGTT was undertaken whilst wearing FSL-CGM to
determine accuracy of the device.
Results: FSL-CGM results were available for 27/28 women with mean data capture 92.8%. There were significant
differences in the ambulatory fasting, post-prandial peaks, and mean glucose between controls in whom both
primary and secondary OGTT was normal (n = 6) and those with two abnormal OGTTs or “true” GDM (n = 7). There
was no difference in ambulatory mean glucose between these controls and the 13 women who had an abnormal
primary OGTT and normal repeat OGTT. These participants had significantly lower body mass index (BMI) than the
true GDM group (29.0 Vs 36.3 kg/m2, p-value 0.014).
Paired OGTT/FSL-CGM readings revealed a Mean Absolute difference (MAD) -0.58 mmol/L and Mean Absolute
Relative Difference (MARD) -11.9%. Bland-Altman plot suggests FSL-CGM underestimated blood glucose by
approximately 0.78 mmol/L.
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Conclusion: Diagnosis of GDM on a single OGTT identifies a proportion of women who do not have a significantly
higher home glucose levels than controls. This raises questions about factors which may affect the reproducibility
of OGTT in this population, including food insecurity and atypical phenotypes of diabetes. More investigation is
needed to understand the suitability of the OGTT as a diagnostic test in sub-Saharan Africa.
Keywords: Gestational diabetes, Non-communicable disease, Africa, Sub-Saharan Africa, Continuous glucose
monitoring, Oral glucose tolerance test, Obstetric medicine
Background
The burden of hyperglycaemia in pregnancy in sub-
Saharan Africa (SSA) is not clear, however several stud-
ies report a prevalence comparable to the well-studied
high-income setting [1]. Indeed, our recent study in
urban and peri-urban central Uganda supports this
(Natamba B, unpublished). These prevalence estimations
are made using the WHO 2013 guidelines which recom-
mend the following criteria for making a diagnosis of
hyperglycaemia in pregnancy using the 2-h oral glucose
tolerance test (OGTT); fasting ≥5.1 and 2-h ≥ 8.5 mmol/
L for gestational diabetes (GDM), and ≥ 7.0 and 2-h ≥
11.1 mmol/L for diabetes in pregnancy (DIP) [2]. How-
ever, these strict glycaemic cut-offs were extrapolated
from the multinational HAPO study which did not in-
clude women in Africa and has not been validated in the
sub-Saharan African setting [3].
Ideally the OGTT should reflect a woman’s ambula-
tory blood glucose levels, which in turn should predict
the chance of poor maternal and perinatal outcomes.
There is concern that a number of factors which are
more common in the sub-Saharan African setting may
lead to misleading OGTT results. For example, food in-
security resulting in low dietary carbohydrate content [4,
5], or a missed or reduced meal size the night preceding
the test [6] have all been shown to induce spurious post-
OGTT hyperglycaemia. Additionally, physical exertion
to reach antenatal clinic, which may reduce fasting glu-
cose results, is common.
Ambulatory continuous glucose monitoring provides
an opportunity to measure a woman’s glycaemic profile
in her home environment [7]. Abbott’s FreeStyle Libre
flash continuous glucose monitoring (FSL-CGM) system
provides accuracy similar to currently available blood
glucose meters. However, these validation studies have
generally been conducted in populations of European
descent in the high-income setting with diabetes outside
of pregnancy [8–11]; FSL-CGM use in pregnant women
in sub-Saharan Africa has not been reported.
The aim of this investigation was to assess how a diag-
nosis of GDM, based on OGTT results, predicts gly-
caemic variables in the home environment. We compare
OGTT results to mean ambulatory glucose, and discrete
fasting and post-prandial periods at home. We also
comment on the usability and accuracy of the device
using paired OGTT and FSL-CGM measurements.
Methods
Study design
This prospective investigation was a nested study within
a larger study of gestational diabetes (unpublished)
which screened 3852 women with OGTT attending
antenatal clinics in Central Uganda. Women for this
nested study were recruited from four sites (Two public;
Kawempe National Referral Hospital, Entebbe Regional
Referral Hospital. Two private; St Francis Hospital
Nsambya, Uganda Martyrs Hospital Lubaga) between
16th August 2018 and 24th May 2019.
The study was performed according to Good Clinical
Practice and the Principles of the Declaration of
Helsinki. The study protocol was approved by Uganda
Virus Research Institute Research and Ethics Committee
(approval GC/127/19/04/625), the Uganda National
Council of Science and Technology (approval HS2340),
and local hospital Institutional Review Boards.
Participants
A total of 28 women who attended antenatal clinic be-
tween 24 and 28 weeks were invited to take part, based
on the results of their initial OGTT in the study. Twenty
cases of ‘GDM’ were included; eleven had high fasting
glucose levels (> 5.1 mmol/L) and nine had high 2-h
OGTT levels (> 8.5 mmol/L) as per the WHO 2013 cri-
teria for a diagnosis of GDM. Eight ‘Controls’ with nor-
mal glucose profiles on initial OGTT were selected for
comparison as controls. Baseline demographic and an-
thropometric characteristics, as detailed below, were col-
lected as part of the main study using standard
equipment and procedures.
Study procedures
Women were fitted with the FSL-CGM device (Freestyle
Libre Flash glucose monitoring system, Abbot Diabetes
Care, Alameda, California, USA) on the back of the
upper arm by study site workers, and given instructions
to scan the device at least every 8 h. Women keep a
diary of their mealtimes at home indicating the time
they consumed either small snacks or large meals. We
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aimed to collect 48–96 h of ambulatory data starting at
least 12 h after the sensor instalment. Women were then
invited to return for a second OGTT whilst the device
remained in place to obtain paired measurements with
reference venous blood glucose.
OGTT was performed as follows: a fasting venous
blood glucose level was taken before participants were
given 82.5 g glucose monohydrate (equivalent to 75 g an-
hydrous glucose) dissolved in 250mls of water. Further
venous blood samples were taken after 1 and 2 h to
measure serum glucose levels. The time was recorded at
each blood draw. Samples for glucose measurement
were immediately centrifuged, and plasma kept on ice.
All samples were analysed centrally at the MRC/UVRI
and LSHTM Clinical and Diagnostics Laboratory in En-
tebbe, within 4 h of collection or stored at − 80 °C for
subsequent analysis.
Statistical procedures
Ambulatory glucose profiles of women with GDM versus
controls
Women were divided into four groups based on the re-
sults of their two OGTTs.
i) Those with two normal OGTTs were labelled as
‘Controls – true’;
ii) those with a normal primary OGTT and abnormal
repeat OGTT were labelled as ‘Controls –
progressed’;
iii) those with an abnormal primary OGTT and normal
repeat OGTT were labelled as ‘GDM – normalised’;
iv) those with two abnormal OGTTs were labelled as
‘GDM – true’.
The ambulatory data from the FreeStyle Libre was
downloaded and analysed using the EasyGV© Software
Version 9.0.R2 [12] to provide mean and standard devi-
ation of home glucose levels. Participants were included
in the ambulatory CGM analysis if the device recorded
> 48 h of ambulatory data and with > 80% of total data
captured. Missing data were interpolated using the
straight-line estimation function of the EasyGV© soft-
ware. Differences in mean glucose and variability (by
standard deviation) between the groups were calculated
with a two-sided t-test using STATA® statistical software
version 15.1 (College Station, Texas).
Fasting and 2-h glucose levels from the second OGTT
were compared to 1) overall mean ambulatory glucose
captured with FSL-CGM and 2) fasting and post-
prandial periods at home. Fasting periods were identified
as > 8 h from the previous meal time, and a maximum of
8 data points (equating to 2 h) were accepted before the
first meal taken. Post-prandial glucose excursions were
identified 1–3 h after a large meal was taken. The mean
of three glucose measurements was taken; the peak level,
and the two levels 15 min either side.
Performance of the Freestyle libre device
The accuracy of the device was determined by compar-
ing the venous blood glucose result from the repeat
OGTT and the most immediate FSL-CGM result that
followed, to account for the reported time lag between
changes in blood and interstitial blood glucose [13]. Cor-
relation is described using Pearson’s correlation coeffi-
cient, Mean absolute relative difference (MARD) and
Mean absolute difference (MAD). We provide percent-
age of paired results satisfying the ISO 15197:2013 cri-
teria [14] which stipulates that 95% of results from the
technology under investigation display a MAD of ±0.83
mmol/L (< 15 mg/dL) when reference glucose < 5.5
mmol/L (< 100 mg/dL) or MARD ±15% when reference
glucose values > 5.5 mmol/L. Results are plotted on the
standard Bland-Altman plot [15].
Results
Participants characteristics
The characteristics of the 28 women recruited into the
study are displayed in Table 1, divided into the ‘GDM’
and ‘Controls’ groups identified by the initial OGTT.
Ambulatory glucose profiles of women with GDM versus
controls
Of the 28 participants, sufficient ambulatory data were
collected on 27 women, with median duration 72 h
(range 48–96 h) and mean (±SD) data capture 92.8% (±
4.6). Missing data clustered around midnight as night-
time presented the longest time period between scan-
ning of the sensor which stores a maximum of 8 h of
data. One participant’s data were excluded due to poor
data capture (< 80%). The mean number of data points
to inform the mean (±SD) ambulatory fasting figure was
21 (±6), and mean (±SD) number of post-prandial peaks
was 5 (±2).
Table 1 Baseline characteristics of study participants
Mean ± SD
n = 28 GDM (n = 20) Controls (n = 8)
Age (years) 29.8 ± 6.7 26.5 ± 4.7
Parity 2.0 ± 1.1 1.3 ± 1.0
Gestation (weeks+days) 26+ 2 ± 1+ 3 26+ 3 ± 1+ 1
Mid-gestational BMI (kg/m2)a 31.5 ± 6.7 31.1 ± 5.2
Haemoglobin (g/dL) 12.4 ± 1.1 12.3 ± 0.9
HbA1c (%) 5.1 ± 0.5 4.9 ± 0.6
HbA1c (mmol/mol) 32.2 ± 5.9 30.0 ± 6.1
Public:private hospital 8:12 3:5
aBMI (Body Mass Index) at recruitment at 24–28 weeks gestation; HbA1c
glycosylated haemoglobin
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The ‘Controls’ group and ‘GDM’ group were divided
based on the results of their repeat OGTT; six women
had two normal OGTTs (‘Controls – true’), one women
had a normal initial OGTT and abnormal repeat OGTT
(‘Controls – progressed’), 13 women had abnormal ini-
tial OGTTs and normal repeat OGTTs (‘GDM – nor-
malised’), and seven women had two abnormal OGTTs
(‘GDM – true’).
The mean ambulatory glucose levels, variability (stand-
ard deviation), and fasting/post-prandial periods captured
by FSL-CGM for the four groups are displayed in Table 2
and Fig. 1. Compared with ‘Controls – true’, there was a
significant difference (p = < 0.05) in the mean ambulatory
glucose (p = 0.027), fasting periods (p = 0.024), and post-
prandial peaks (p = 0.041) of women identified as ‘GDM –
true’. There was no difference in the mean glucose, vari-
ability, and fasting periods of the women identified as
‘GDM – normalised’, though there was a significant differ-
ence in the post-prandial peaks (p = 0.003). These partici-
pants whose OGTT normalised had significantly lower
mid-gestational BMI than those who had confirmed GDM
on two OGTTs (BMI 29.0 Vs 36.3, p-value 0.014).
Performance of the Freestyle libre device
22/28 women completed the full time period without
problems with the FSL-CGM device. Of the remaining
six; three sensors were accidently removed (one trapped
in a door, another dislodged whilst washing, another
with no trauma), two showed an ‘error’ message, and
one was removed on request of her partner. We ob-
tained matched FSL-CGM/OGTT data for 17 women
out of the 28 who completed a repeat OGTT whilst
wearing the device. Of the remaining eleven; six had
technical issues as stated above, two sensors were not
scanned post-OGTT due to staff error and so data was
lost, and three women had their repeat OGTT immedi-
ately after the FSL-CGM device was fitted, before the
protocol was revised; these data were excluded due to
known sensor inaccuracy at this time [13].
The relationship between FSL-CGM interstitial glu-
cose and venous blood glucose during the OGTT is
shown in Table 3. The mean (±SD) delay between the
venous blood glucose result and the interstitial FSL-
CGM result was 7.4 (±5.3) minutes. The overall correl-
ation (95% CI) between CGM glucose and venous glu-
cose for combined fasting, 1-h and 2-h results was 0.81
(0.69–0.89). Overall 49% results met the ISO 2013 cri-
teria, using MAD for the 21/51 results < 5.5 mmol/L and
MARD for the 30/51 results > 5.5 mmol/L. Bland-
Altman plot is displayed in Fig. 2.
Discussion
Summary
Our study describes potential shortfalls of the OGTT when
used in the sub-Saharan African setting. Whilst the OGTT
successfully predicted higher ambulatory glycaemic values
in women consistently diagnosed with GDM on two
OGTTs, there was a significant proportion of women with
only one abnormal OGTT and who did not display signifi-
cant elevations in ambulatory mean glucose levels. How-
ever, these women still had significantly higher home post-
prandial glycaemic excursions than controls, suggesting
that they may have subtle abnormalities in glucose control.
Moreover, these women were of lower BMI compared to
the true GDM group. These observations indicate chal-
lenges in reproducibility of OGTT in this population, par-
ticularly in individuals with low BMI.
The FreeStyle Libre flash glucose monitoring (FSL-
CGM) technology was highly acceptable to pregnant
women living in Kampala, Uganda. However, attrition
rate due to sensor loss was high. The device modestly
underestimates venous blood glucose and displays a
higher mean average deviation than initial accuracy
studies of the device under laboratory conditions; this
will require further investigation in similar populations.
Table 2 Differences in ambulatory glucose measurements of participants in the four groups
Controls Controls GDM p-value* GDM p-value*
True Progressed Normalised True
Total n = 27 n = 6 n = 1 n = 13 n = 7
Mean glucose (mmol/L) 3.87 6.75 4.26 0.22 4.90 0.03
Standard deviation 0.28 – 0.71 0.95
Mean variability (SD) 0.92 1.42 1.13 0.42 1.11 0.22
Standard deviation 0.15 – 0.25 0.33
Fasting periods (mmol/L) 3.27 6.05 3.40 0.63 4.26 0.02
Standard deviation 0.40 – 0.58 0.85
Post-prandial peaks (mmol/L) 5.38 9.27 6.44 < 0.01 6.82 0.04
Standard deviation 0.46 – 0.69 1.46
*compared with ‘Controls – true’ group
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Ambulatory glucose profiles of women with GDM versus
controls
In our study, the OGTT successfully predicted higher
mean ambulatory glucose levels, fasting levels, and post-
prandial peaks in women with GDM confirmed on re-
peat OGTT testing. We are not aware of any other stud-
ies that make such a comparison, particularly not in this
setting. The majority of studies in pregnancy have been
designed to test the utility of CGM devices in women in
high-income countries (HICs) already diagnosed with
type 1 or type 2 diabetes to reduce glycaemic indices
such as HbA1c and poor perinatal outcomes [16–19]. A
small study in patients with cystic fibrosis [20] compared
OGTT with CGM results, and found some overlap of
glucose levels in those with normal OGTT results and
those deemed to have impaired glucose tolerance, as we
did in our study. A small study in Japan [21] compared
CGM results in women diagnosed with GDM on 1 h
Fig. 1 Boxplot showing distribution of mean ambulatory glucose and variability (standard deviation) derived from FSL-CGM results for the four
groups. Boxes represent interquartile range, whiskers represent variability, and horizontal bars represent the median value. Individuals are
presented as dots. Light blue = ‘Controls – true’; Dark blue = ‘Controls – progressed’; Yellow = ‘GDM – normalised’; Red = ‘GDM – true’
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and 2 h OGTT results and found a higher SD in gly-
caemic profiles, though they only included two controls.
Both these studies used the Medtronic iPro™2 technol-
ogy, and not the FreeStyle Libre as we did.
A large proportion (13/20) of our participants initially
diagnosed with GDM had normal OGTTs despite three
further weeks of gestation and only basic dietary advice.
They had similar mean glucose levels, variability and
fasting levels to the true control group. However, they
displayed significantly higher post-prandial peaks at
home. This might suggest that the OGTT, using the
new stricter WHO 2013 diagnostic criteria, may be
over-sensitive in diagnosing GDM in women who do
not have significantly elevated mean glucose levels at
home. Alternatively, it could be argued that there had
been improvement in glycaemic control, perhaps from
lifestyle changes after the initial diagnosis; one could also
argue this is offset by increasing gestation of an average
of 3 weeks. However, this discrepancy may also relate to
challenges of OGTT reproducibility in a population
where food insecurity remains important. Indeed, there
is increasing evidence that the OGTT may be affected
by carbohydrate intake during the day(s) preceding the
test [4–6]. Secondly this may be a clue that the women
falsely identified as GDM may be reflective of an atypical
phenotype of diabetes more commonly found in sub-
Saharan African populations associated with setting-
specific causes of low beta-cell reserve such as in-utero
and childhood malnutrition, and inflammation related to
chronic infections [22, 23]. Notably, the participants
whose OGTTs normalised had significantly lower mid-
gestational BMI than those who had confirmed GDM.
Table 3 Comparison of interstitial glucose measured by FSL-CGM and reference venous blood glucose based on standard analytical
approaches
Fasting (n = 17) 1 h post-OGTT (n = 17) 2 h post-OGTT (n = 17) All (n = 51)
Time difference between paired samples ± SD (minutes) 8.8 ± 5.4 5.3 ± 5.0 7.9 ± 5.2 7.4 ± 5.3
Correlation coefficient (95% CI) 0.57 (0.12–0.83) 0.68 (0.30–0.88) 0.66 (0.26–0.87) 0.81 (0.69–0.89)
MAD overall (mmol/L) −0.54 − 0.92 −0.89 − 0.78
MAD when ref. < 5.5 mmol/L (n = 21) −0.58
MARD overall (%) −12.2 −11.3 −13.2 −12.3
MARD when ref. > 5.5 mmol/L (n = 30) −11.9
Within ISO 2013 criteria (%) 58.8 41.2 47.1 49.0
SD standard deviation; CI confidence interval; MAD mean absolute difference; MARD mean absolute relative difference; ISO international organization
of standardization
Fig. 2 Bland-Altman plot comparing interstitial glucose with FSL-CGM and reference venous blood glucose. Overall FSL-CGM underestimated
blood glucose by 0.78 mmol/L, with 95% limits of agreement (LOA) from − 3.18 to 1.62 mmol/L.
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However, this theory does not explain the normalisation
of the OGTT on repeat testing.
Performance of the Freestyle libre device
We are aware of one other study reporting real-world
usability of the FSL-CGM in sub-Saharan Africa, in Jo-
hannesburg, South Africa [24]. They describe similar lo-
gistical issues to our own report in that 17/73 (23%) of
participants encountered either sensor failure or early
removal of the sensor, comparable to our own 6/28
(21%). This compares to 0/73 in a study in pregnant
women in England [25] and 49/80 sensor loss in a study
in Beijing [26] though this was over a full 2 week period.
We postulate this may be secondary to environmental
conditions or the physical nature of domestic life in
Uganda.
We applied standard metrics for assessment and com-
parison with other studies [27]. We report similar MAD
(0.58 mmol/L) and MARD (11.9%) values to the original
performance papers [9, 10, 25, 26, 28] though the last
two studies used capillary rather than venous blood glu-
cose as a reference comparator. However, variable accur-
acy is hidden within these mean values; we report
inferior accuracy with lower percentage of values fulfill-
ing ISO criteria (49% Vs 73.2% [10]). A clear difference
is that these other studies were investigating people with
established diabetes, with higher glucose concentrations.
However, the discrepancy in accuracy still remains when
looking at the sub-group analysis of accuracy at lower
glucose concentrations too. Our Bland-Altman plot de-
scribes the tendency of FSL-CGM to underestimate ven-
ous blood glucose in our study. This reflects other
published data which describes this technology reading
‘low’ during eu- or hypoglycaemia [10, 13], particularly
at night.
Strengths
Our study is the first to compare OGTT results to am-
bulatory glycaemic profiles in this setting, which is more
likely to reflect the situation in other low-income coun-
tries where women take part in physical domestic duties
and still consume a traditional diet. It is also the first
study to assess this technology in the environmental
conditions of SSA, with temperatures above the product
storage specification (Abbott advise < 25 degrees Celsius
[29]) and similar levels of physical domestic life not
reflected under previous strict trial conditions.
Secondly, as this was a nested study within a large in-
vestigation of hyperglycaemia in pregnancy, we have
taken advantage of robust study protocols and laboratory
assessment. Samples from different study sites were han-
dled appropriately with immediate local centrifugation
and rapid analysis at the MRC/UVRI and LSHTM cen-
tral laboratory which maintains strict quality control
standards. A strong system for analysing the reference
sample is imperative to any study, particularly when
commenting on performance and accuracy of new
technology.
Weaknesses
The study was limited by the small number of partici-
pants involved. A larger study would be needed to make
strong conclusions about the ability of the OGTT to
predict ambulatory glycaemic load, though we offer im-
portant insights. Again, accuracy studies would also
benefit from a larger number of participants as was done
in previous performance studies of the technology. It
should be noted that the study was not specifically de-
signed to test the reproducibility of the OGTT.
Our results may be affected by our assessment during
time periods where the technology is reported to exhibit
diminished accuracy, namely hypo- (< 4.0 mmol/L) or
euglycaemia (4.0-10 mmol/L) [10, 13]. The GDM cases
we selected were ‘mild’ and displayed relatively normal
glycaemic profiles for much of the day, and so accuracy
may be diminished compared to the other studies asses-
sing higher glucose concentrations in overt diabetes. We
found many results FSL-CGM displaying ‘2.8 mmol/L’,
the lower limit of the sensor, particularly overnight.
These are unlikely to be true values, rather the technol-
ogy displaying an inaccurate underestimation which may
be due to compression of the sensor as described else-
where. Whilst unlikely to be accurate values they would
have affected the results of mean glucose burden in
some of our participants. Our accuracy assessment may
also have been hampered by taking measurements dur-
ing the OGTT as previous studies suggest that accuracy
of the device is also diminished during rapid changes in
glucose level [11, 30]. One might argue it is not fair to
comment on accuracy solely during an OGTT, and it
may be valuable to assess accuracy with paired glucose
results throughout the day. Though this may provide a
fairer assessment of performance, it would demand ex-
tended periods of time for women to attend the study
site.
Future work
The ultimate question remains; what test, or combin-
ation of tests, should be deployed to optimise detection
of hyperglycaemia in pregnancy in sub-Saharan Africa?
The OGTT is an expensive and laborious test to use in
the resource limited setting, and its use with the WHO
2013 diagnostic criteria must be adequately studied be-
fore being rolled out in this population. More work is
needed to understand whether our results represent im-
provement in glycaemic indices with basic dietary advice,
or indeed unreliability of the OGTT in this population.
We also do not yet know whether women with normal
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OGTT but high glucose excursions at home suffer worse
pregnancy outcomes.
This is the first reported use of this technology in
sub-Saharan Africa, other than South Africa. We
await to see if our findings are reproduced in other
populations, or with other CGM technology, and
methods by which we may reduce sensor attrition
rates in this setting.
Conclusion
New CGM technology offers the opportunity to assess
the glycaemic profiles of pregnant women with GDM
in everyday life. We describe potential inadequacies of
the OGTT to diagnose GDM in the sub-Saharan Afri-
can setting, and suggest this may be due to physical
and dietary conditions around the time of the OGTT,
or the existence of atypical phenotypes of diabetes
more common in this setting. Our team is in the
process of conducting other studies to further test
these hypotheses.
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